Summary:
WORRIED ABOUT SICKLE CELL DISEASE?
While current treatments for sickle cell disease (SCD) help some people, there is a need for additional treatments. That’s why researchers are conducting the STRONG SCD study. It is a clinical study evaluating an oral investigational drug designed to lessen SCD complications, including pain crises.
The STRONG SCD study is for people who have had at least one pain crisis (pain episode) in the past year. If they are currently on a stable dose of an approved treatment for SCD, they may be able to continue taking it while participating in the study.
OVERVIEW OF THE STRONG SCD STUDY
The study is for ages 16-70. It is evaluating an oral investigational drug designed to lessen SCD complications.
Sickle cell disease is an inherited red blood cell disorder that causes red blood cells to deform into a sickle shape, impacting blood flow to organs and tissues. The investigational drug is designed to increase the production of cGMP, something the body produces naturally. Researchers believe that increasing cGMP may help improve blood flow and reduce inflammation while boosting the number of healthy red blood cells in people with sickle cell disease. By doing so, they believe that more nutrients will be able to get to the critical organs that need them, lessening the risk for disease complications.
KEY ELIGIBILITY CRITERIA:
- Adolescents, men and women 16-70 years old
- Diagnosed with sickle cell disease
- At least one pain crisis in the past year
ALL STUDY PARTICIPANTS WILL RECEIVE AT NO COST:
- Investigational drug or placebo
- Study-related care, medical tests and assessments
- Visits with a doctor experienced in treating SCD
Participants may be reimbursed for their time and travel.